ALK- and RET-Positive NSCLC Treatments: New Agents Challenge Market Leaders as Efficacy Data Shifts Investment Priorities In May 2026, emerging therapies for ALK- and RET-positive non-small cell lung cancer (NSCLC) intensified competitive pressure on established drugs like Lorbrena (Pfizer), with 7-year progression-free survival (PFS) data boosting investor confidence. This development reshapes oncology treatment paradigms and redefines market dynamics for biotech and pharma stakeholders.
The recent 7-year follow-up data from Pfizer’s CROWN trial, showing a 55% PFS rate for Lorbrena in ALK-positive NSCLC, underscores the drug’s durability. However, newer agents targeting RET mutations—such as LOXO-292 (Loxo Oncology) and Gavreto (LOXO-292’s commercial counterpart)—are gaining traction, threatening to erode Pfizer’s market share. These developments are prompting a reevaluation of R&D investments and M&A strategies in the oncology sector.
The Bottom Line
- Pfizer’s Lorbrena holds 68% market share in ALK-positive NSCLC, but newer RET inhibitors could capture 15-20% by 2028.
- Biotech firms with RET-targeting pipelines, like Array Biopharma, saw a 12% stock surge post-ASCO 2026 data.
- Analysts warn that 7-year PFS data may not offset rising R&D costs, with 30% of oncology firms facing margin pressures in 2027.
How Clinical Efficacy Translates to Market Valuation
The CROWN trial’s 7-year PFS data for Lorbrena, reported at 55%, outperforms the 35% PFS of earlier-generation ALK inhibitors. However, this edge is narrowing as newer agents demonstrate superior intracranial activity and fewer resistance mutations. For instance, LOXO-292’s 72% PFS at 24 months in RET-positive NSCLC, per ASCO 2026, signals a shift in treatment benchmarks.
Here is the math: Lorbrena’s 2025 revenue was $2.1 billion, with a 14.2% YoY growth. However, its EBITDA margin contracted 3.5% due to increased R&D spending on next-gen therapies. Meanwhile, Loxo Oncology, acquired by Eli Lilly in 2020, reported a 22% revenue increase in Q1 2026, driven by LOXO-292’s expanding label. This divergence highlights the financial risks of relying on single-molecule solutions in a rapidly evolving market.
The Balance Sheet Dilemma: R&D vs. Profitability
Biotech companies face a critical trade-off: investing in next-generation therapies or maintaining profitability. For example, Array Biopharma (NASDAQ: ARRY), which owns Gavreto, spent $450 million on RET-targeted R&D in 2025, pushing its net loss to $180 million. In contrast, Roche (SIX: ROG), with a broader oncology portfolio, achieved a 28% EBITDA margin in 2025, leveraging its immuno-oncology assets.
But the balance sheet tells a different story. Pfizer (NYSE: PFE)’s 2025 capital expenditure on oncology R&D rose 19%, with $1.2 billion allocated to ALK/RET programs. This strategy, while risky, aligns with the company’s goal to maintain dominance in a $12.4 billion global NSCLC therapeutics market. However, analysts at Goldman Sachs note that “Pfizer’s high R&D burn rate could strain free cash flow if new therapies fail to meet Phase III endpoints.”
Market-Bridging: Supply Chains, Inflation, and Investor Sentiment
The NSCLC treatment landscape is intertwined with broader macroeconomic trends. Rising drug development costs—up 21% since 2020—have exacerbated inflationary pressures in healthcare
